<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25813631</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>EV71 infection correlates with viral IgG preexisting at pharyngo-laryngeal mucosa in children.</ArticleTitle><Pagination><StartPage>146</StartPage><EndPage>152</EndPage><MedlinePgn>146-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12250-014-3555-2</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) infection causes severe central nervous system damage, particularly for children under the age of 5 years old, which remains a major public health burden worldwide. Clinical data released that children may be repeatedly infected by different members in enterovirus and get even worsen. Mucosa, especially epithelium of alimentary canal, was considered the primary site of EV71 infection. It has been elusive whether the preexsiting viral antibody in mucosa plays a role in EV71 infection. To answer this question, we respectively measured viral antibody response and EV71 RNA copy number of one hundred throat swab specimens from clinically confirmed EV71-infected children. The results released that low-level of mucosal IgG antibody against EV71 broadly existed in young population. More importantly, it further elucidated that the children with mucosal preexsiting EV71 IgG were prone to be infected, which suggested a former viral IgG mediated enhancement of viral infection in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jingchang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Changzhou Center for Disease Control and Prevention, Changzhou, 213022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaoming</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiaoyi</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Hu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Huimin</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007820" MajorTopicYN="N">Laryngeal Mucosa</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010614" MajorTopicYN="N">Pharynx</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25813631</ArticleId><ArticleId IdType="pmc">PMC8200873</ArticleId><ArticleId IdType="doi">10.1007/s12250-014-3555-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bell EJ, McCartney RA. A study of Coxsackie B virus infections, 1972&#x2013;1983. J Hyg (Lond) 1984;93:197&#x2013;203. doi: 10.1017/S0022172400064718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022172400064718</ArticleId><ArticleId IdType="pmc">PMC2129449</ArticleId><ArticleId IdType="pubmed">6094660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, Devillier, Cong Z, Wei Q, Gao H, Qin C, Yang GB, Zurbriggen, Lopalco L, Fleury S. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34:269&#x2013;280. doi: 10.1016/j.immuni.2011.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.01.015</ArticleId><ArticleId IdType="pubmed">21315623</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao RY, Dong DY, Liu RJ, Han JF, Wang GC, Zhao H, Li XF, Deng YQ, Zhu SY, Lin F, Zhang FJ, Chen W, Qin ED, Qin CF. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One. 2013;8:e64024. doi: 10.1371/journal.pone.0064024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen IC, Wang SM, Yu CK, Liu CC. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol. 2013;202:259&#x2013;265. doi: 10.1007/s00430-013-0289-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-013-0289-y</ArticleId><ArticleId IdType="pubmed">23408291</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin. 2011;26:221&#x2013;228. doi: 10.1007/s12250-011-3195-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-011-3195-8</ArticleId><ArticleId IdType="pmc">PMC8222466</ArticleId><ArticleId IdType="pubmed">21847753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Girn J, Kavoosi M, Chantler J. Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J Gen Virol. 2002;83:351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">11807228</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, O&#x2019;Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265:739&#x2013;741. doi: 10.1038/265739a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/265739a0</ArticleId><ArticleId IdType="pubmed">404559</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Deng YQ, Tian X, Jiang T, Qin ED, Qin CF. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J. 2011;8:106. doi: 10.1186/1743-422X-8-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341:929&#x2013;935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hober D, Chehadeh W, Bouzidi A, Wattre P. Antibody-dependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-synthesis. J Infect Dis. 2001;184:1098&#x2013;1108. doi: 10.1086/323801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/323801</ArticleId><ArticleId IdType="pubmed">11598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Yi L, Su J, Lu J, Ke C, Zeng H, Guan D, Ma C, Zhang W, Xiao H, Li H, Lin J, Zhang Y. Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period. PLoS One. 2013;8:e80515. doi: 10.1371/journal.pone.0080515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0080515</ArticleId><ArticleId IdType="pmc">PMC3850913</ArticleId><ArticleId IdType="pubmed">24324604</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZL, Palaniyandia S, Zeng RY, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci. 2011;108:4388&#x2013;4393. doi: 10.1073/pnas.1012861108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1012861108</ArticleId><ArticleId IdType="pmc">PMC3060240</ArticleId><ArticleId IdType="pubmed">21368166</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Wang S, Yang R, Ou X. A case-control study of risk factors for severe hand-foot-mouth disease in Yuxi, China, 2010&#x2013;2012. Virol Sin. 2014;29:123&#x2013;125. doi: 10.1007/s12250-014-3384-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-014-3384-3</ArticleId><ArticleId IdType="pmc">PMC8206253</ArticleId><ArticleId IdType="pubmed">24643937</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in western Australia. Clin Infect Dis. 2001;32:236&#x2013;242. doi: 10.1086/318454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318454</ArticleId><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794&#x2013;797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch M, Roos R. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Knipe D, Howley P, editors. In Fields Virology. 4th edn. Baltimore: Williams and Wilkins; 2001. pp. 840&#x2013;893.</Citation></Reference><Reference><Citation>Sun Y, Shi W, Yang JY, Zhou D, Chen Y, Zhang Y, Yang Y, He B, Zhong M, Li Y, Cao Y, Xiao Y, Yu J, Li Y, Fan M, Yan H. Flagellin-PAc fusion protein is a high efficacy anti-caries mucosal vaccine. J Dent Res. 2012;91:941&#x2013;947. doi: 10.1177/0022034512457684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0022034512457684</ArticleId><ArticleId IdType="pubmed">22895510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirado SM, Yoon KJ. Antibody dependent enhancement of virus infection and disease. Viral Immunol. 2003;16:69&#x2013;86. doi: 10.1089/088282403763635465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/088282403763635465</ArticleId><ArticleId IdType="pubmed">12725690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Chen IC, Su LY, Huang KJ, Lei HY, Liu CC. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol. 2010;17:1517&#x2013;1523. doi: 10.1128/CVI.00108-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00108-10</ArticleId><ArticleId IdType="pmc">PMC2953001</ArticleId><ArticleId IdType="pubmed">20685937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Ho TS, Lin HC, Lei HY, Wang JR, Liu CC. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis. 2012;31:1219&#x2013;1224. doi: 10.1007/s10096-011-1432-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-011-1432-6</ArticleId><ArticleId IdType="pubmed">21983920</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798&#x2013;801. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Zhang Y, Li Q, Chen Y, He B, Yang J, Tu H, Lei L, Yan H. Matrix protein-specific IgA antibody inhibits measles virus replication by intracellular neutralization. J Virol. 2011;85:11090&#x2013;11097. doi: 10.1128/JVI.00768-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00768-11</ArticleId><ArticleId IdType="pmc">PMC3194966</ArticleId><ArticleId IdType="pubmed">21865386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>